Stereochemical and steric control of the UDP-glucuronosyltransferase- catalyzed conjugation reaction: A rational approach for the design of inhibitors for the human UGT2B7

ChemMedChem

Volumn 2, Issue 12, 2007, Pages 1730-1740

  Bichlmaier, Ingo ^a   Finel, Moshe ^a   Sippl, Wolfgang ^b   Yli Kauhaluoma, Jari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

3D QSAR; Eudismic analysis; Inhibition; Metabolism; UGT

Indexed keywords

ENZYME INHIBITOR; GLUCURONOSYLTRANSFERASE; UGT2B7 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; HUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

CATALYSIS; DRUG DESIGN; ENZYME INHIBITORS; GLUCURONOSYLTRANSFERASE; HUMANS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 48849084735     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200700122     Document Type: Article

References (39)

1. For reviews, see: a) A. Radominska-Pandya, M. Ouzzine, S. Fournel-Gigleux, J. Magdalou, Methods Enzymol. 2005, 400, 116-147;
2. b) P. G. Wells, P. I. Mackenzie, J. R. Chowdhury, C. Guillemette, P. A. Gregory, Y. Ishii, A. J. Hansen, F. K. Kessler, P. M. Kim, N. R. Chowdhury, J. K. Ritter, Drug Metab. Dispos. 2004, 32, 281-290;
3. c) M. B. Fisher, M. F. Paine, T. J. Strelevitz, S. A. Wrighton, Drug Metab. Rev. 2001, 33, 273-297;
4. d) C. D. King, G. R. Rios, M. D. Green, T. R. Tephly, Curr. Drug Metab. 2000, 1, 143-161.
5. The term catalytic promiscuity has been originally used to describe the ability of an enzyme to catalyze an adventitious secondary activity at the active site responsible for the primary activity (see S. D. Copley, Curr. Opin. Chem. Biol. 2003, 7, 265-272). However, in the case of metabolic enzymes like UGTs the term has been used to depict their overlapping substrate selectivities.
6. a) I. S. Owens, N. K. Basu, R. Banerjee, Methods Enzymol. 2005, 400, 1-22;
7. b) J. A. Williams, R. Hyland, B. C. Jones, D. A. Smith, S. Hurst, T. C. Goosen, V. Peterkin, J. Koup, S. E. Ball, Drug Metab. Dispos. 2004, 32, 1201-1208;
8. c) P. I. Mackenzie, K. W. Bock, B. Burchell, C. Guillemette, S.-I. Ikushiro, T. Iyanagi, J. O. Miners, I. S. Owens, D. W. Nebert, Pharmacogenet. and Genomics 2005, 15, 677-685.
9. A. Rowland, P. Gaganis, D. J. Elliot, P. I. Mackenzie, K. M. Knights, J. O. Miners, J. Pharmacol. Exp. Ther. 2007, 321, 137-147.
10. K. Grancharov, Z. Naydenova, S. Lozeva, E. Golovinsky, Pharmacol. Ther. 2001, 89, 171-186.
11. a) C. M. Timmers, M. Dekker, R. C. Buijsman, G. A. van der Marel, B. Ethell, G. Anderson, B. Burchell, G. J. Mulder, J. H. van Boom, Bioorg. Med. Chem. Lett. 1997, 7, 1501-1506;
12. b) D. Noort, E. A. Meijer, T. J. Visser, J. H. Meerman, G. A. van der Marel, J. H. van Boom, G. J. Mulder, Mol. Pharmacol. 1991, 40, 316-320.
13. V. L. Schramm, Curr. Opin. Struct. Biol. 2005, 15, 604-613.
14. V. L. Schramm, Annu. Rev. Biochem. 1998, 67, 693-720.
15. a) M. Said, D. Noort, J. Magdalou, J. C. Ziegler, G. A. van der Marel, J. H. van Boom, G. J. Mulder, G. Siest, Biochem. Biophys. Res. Commun. 1992, 187, 140-145;
16. b) D. Noort, M. W. Coughtrie, B. Burchell, G. A. van der Marel, J. H. van Boom, A. van der Gen, G. J. Mulder, Eur. J. Biochem. 1990, 188, 309-312;
17. c) D. K. Alargov, R. G. Gugova, P. S. Denkova, G. MSller, E. V. Golovinsky, Monatsh. Chem. 1999, 130, 937-943;
18. d) D. K. Alargov, Z. Naydenova, K. Grancharov, P. S. Denkova, E. V. Golovinsky, Monatsh. Chem. 1997, 128, 725-732;
19. e) D. K. Alargov, Z. Naydenova, K. Grancharov, P. Denkova, E. Golovinsky, Monatsh. Chem. 1998, 129, 755-760.
20. a) I. Bichlmaier, A. Siiskonen, M. Finel, J. Yli-Kauhaluoma, J. Med. Chem. 2006, 49, 1818-1827;
21. b) I. Bichlmaier, A. Siiskonen, M. Kurkela, M. Finel, J. Yli-Kauhaluoma, Biol. Chem. 2006, 387, 407-416;
22. c) I. Bichlmaier, Drug Metab. Rev. 2006, 38 (Suppl. 2), 185-186.
23. I. Bichlmaier, M. Kurkela, A. Siiskonen, M. Finel, J. Yli-Kauhaluoma, Bioorg. Chem. 2007, 35, 386-400.
24. R. D. Cramer, D. E. Patterson, J. D. Bunce, J. Am. Chem. Soc. 1988, 110, 5959-5967.
25. a) M. J. Sorich, R. A. McKinnon, J. O. Miners, D. A. Winkler, P. A. Smith, J. Med. Chem. 2004, 47, 5311-5317;
26. b) M. J. Sorich, J. O. Miners, R. A. McKinnon, D. A. Winkler, F. R. Burden, P. A. Smith, J. Chem. Inf. Comput. Sci. 2003, 43, 2019-2024;
27. c) M. J. Sorich, P. A. Smith, D. A. Winkler, F. R. Burden, R. A. McKinnon, J. O. Miners, Drug Metab. Rev. 2003, 35 (Suppl. 2), 333.
28. G. Klebe, U. Abraham, T. Mietzner, J. Med. Chem. 1994, 37, 4130-4146.
29. M. Bohm, J. Stürzebecher, G. Klebe, J. Med. Chem. 1999, 42, 458-477.
30. MOE Molecular Modeling Software, version 2006.8; Chemical Computing Group, Montreal, Canada.
31. SYBYL Molecular Modeling Software, version 7.2; Tripos Inc., St. Louis, USA.
32. W. Sippl, J. Comp.-Aided Mol. Des. 2000, 14, 559-572.
33. Eudismic analysis investigates the interaction between chiral compounds and their biological targets. This analytical method is used in drug design and development to increase the selectivity and potency of a chiral lead compound toward the pharmacological target. The term eudismic analysis was derived from the expressions eutomer and distomer. The more biologically active stereoisomer is termed eutomer, the less active one is called distomer. See: a) R. Crossley, Chirality and the biological activity of drugs, CRC, Boca Raton, 1995, p. 196;
34. b) M. Eichelbaum, B. Testa, A. Somogyi, Stereochemical aspects of drug action and disposition, Springer-Verlag, Berlin, 2003, p. 442.
35. The eudismic ratio was calculated by dividing the amount of formed eutomer glucuronide by the amount of formed distomer glucuronide. The eudismic ratio therefore expressed the preferential formation of the glucuronide of one compound over that of its respective stereoisomer.
36. M. Kurkela, A. Garcia-Horsman, L. Luukkanen, S. Mörsky, J. Taskinen, M. Baumann, R. Kostiainen, J. Hirvonen, M. Finel, J. Biol. Chem. 2003, 278, 3536-3544.
37. a) I. Bichlmaier, M. Kurkela, T. Joshi, A. Siiskonen, T. Rüffer, H. Lang, B. Suchanová, M. Vahermo, M. Finel, J. Yli-Kauhaluoma, J. Med. Chem. 2007, 50, 2655-2664;
38. b) I. Bichlmaier, M. Kurkela, T. Joshi, M. Finel, J. Yli-Kauhaluoma, ChemMedChem. 2007, 2, 881-889.
39. S. Kaivosaari, J. S. Salonen, J. Mortensen, J. Taskinen, Anal. Biochem. 2001, 292, 178-187.